BioSpace News Archive

Marrone Bio Innovations, Inc., an international leader in sustainable bioprotection and plant health solutions, announced a transition of its Chief Financial Officer role.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines announced a distribution service agreement with Adium Pharma S.A., a leading private Latin American pharmaceutical company, to support the commercialization of the Moderna COVID-19 vaccine, Spikevax across Latin America.

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, highlighted the ability of its CNSide™ cerebrospinal fluid (CSF) assay to aid in therapeutic research programs for metastatic brain cancer in a presentation at the Molecular & Precision Med Tri-Con meeting.

Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Sarah Yuan, Ph.D., as Chief Technical Operations Officer, effective March 7th, 2022.

OncoSec Medical Incorporated, a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer, announced the appointment of George Chi as Chief Financial Officer.

Arima Genomics, Inc., the leader in 3D genomics, today announced the launch of new solutions for structural variant detection and gene regulation analysis.

Neuronetics, Inc. announced it has amended its term loan agreement with its current lenders, investment affiliates managed by SLR Investment Corp., which was originally entered into on March 2, 2020 and subsequently amended on April 20, 2020 and December 2, 2020.

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming virtual Cowen 42nd Annual Health Care Conference.

Gracell Biotechnologies Inc. today announced multiple advancements of its TruUCAR platform, the Company’s proprietary technology platform designed to generate high-quality allogeneic CAR-T cell therapies that can be administered “off-the-shelf” as stand-alone therapy at lower cost and with greater convenience.

Biohaven Pharmaceutical Holding Company Ltd. today announced that it has commenced enrollment in a Phase 2/3 clinical trial assessing the efficacy and safety of Nurtec® ODT (rimegepant) 75 mg in patients with chronic rhinosinusitis (CRS) with or without nasal polyps.